Traders purchased shares of Eli Lilly and Company (NYSE:LLY) on weakness during trading hours on Monday. $95.07 million flowed into the stock on the tick-up and $54.90 million flowed out of the stock on the tick-down, for a money net flow of $40.17 million into the stock. Of all stocks tracked, Eli Lilly and had the 11th highest net in-flow for the day. Eli Lilly and traded down ($0.29) for the day and closed at $82.63
LLY has been the subject of a number of analyst reports. Berenberg Bank reaffirmed a “buy” rating and issued a $98.00 price target on shares of Eli Lilly and in a report on Friday, August 4th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $89.00 price target on shares of Eli Lilly and in a report on Monday. Sanford C. Bernstein reaffirmed an “outperform” rating and issued a $88.00 price target on shares of Eli Lilly and in a report on Sunday, May 21st. TheStreet downgraded shares of Eli Lilly and from a “b+” rating to a “c” rating in a report on Wednesday, May 31st. Finally, BMO Capital Markets reaffirmed an “underperform” rating and issued a $73.00 price target on shares of Eli Lilly and in a report on Wednesday, July 26th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $88.07.
The company has a 50-day moving average price of $80.88 and a 200 day moving average price of $82.06. The company has a market cap of $87.17 billion, a price-to-earnings ratio of 35.76 and a beta of 0.34.
Eli Lilly and (NYSE:LLY) last released its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.05 by $0.06. The business had revenue of $5.82 billion for the quarter, compared to the consensus estimate of $5.60 billion. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The business’s revenue was up 7.8% on a year-over-year basis. During the same period in the previous year, the firm earned $0.86 EPS. On average, equities research analysts anticipate that Eli Lilly and Company will post $4.16 EPS for the current year.
The business also recently declared a quarterly dividend, which was paid on Friday, September 8th. Stockholders of record on Tuesday, August 15th were paid a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.52%. The ex-dividend date of this dividend was Friday, August 11th. Eli Lilly and’s dividend payout ratio (DPR) is 90.04%.
In other news, major shareholder Lilly Endowment Inc sold 210,000 shares of the business’s stock in a transaction that occurred on Thursday, June 22nd. The shares were sold at an average price of $84.43, for a total value of $17,730,300.00. Following the sale, the insider now directly owns 124,265,804 shares of the company’s stock, valued at approximately $10,491,761,831.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold a total of 825,000 shares of company stock worth $68,456,650 over the last three months. Insiders own 0.20% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the company. Acrospire Investment Management LLC raised its stake in shares of Eli Lilly and by 16.7% in the 2nd quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock valued at $115,000 after acquiring an additional 200 shares during the period. San Francisco Sentry Investment Group CA purchased a new stake in Eli Lilly and during the 2nd quarter worth approximately $129,000. Heritage Trust Co purchased a new stake in Eli Lilly and during the 1st quarter worth approximately $135,000. Point72 Asia Hong Kong Ltd increased its stake in Eli Lilly and by 237.4% during the 1st quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock worth $148,000 after buying an additional 1,239 shares during the period. Finally, Shine Investment Advisory Services Inc. purchased a new stake in Eli Lilly and during the 2nd quarter worth approximately $148,000. 75.77% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: This article was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this article on another site, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The correct version of this article can be viewed at https://sportsperspectives.com/2017/09/11/investors-buy-shares-of-eli-lilly-and-company-lly-on-weakness.html.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.